208 related articles for article (PubMed ID: 11429164)
1. Recombinant, soluble LIGHT (HVEM ligand) induces increased IL-8 secretion and growth arrest in A375 melanoma cells.
Hehlgans T; Männel DN
J Interferon Cytokine Res; 2001 May; 21(5):333-8. PubMed ID: 11429164
[TBL] [Abstract][Full Text] [Related]
2. Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling.
An MM; Fan KX; Zhang JD; Li HJ; Song SC; Liu BG; Gao PH; Zhou Q; Jiang YY
Pharmacol Res; 2005 Sep; 52(3):234-44. PubMed ID: 15925518
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.
Chang YH; Hsieh SL; Chao Y; Chou YC; Lin WW
J Biomed Sci; 2005; 12(2):363-75. PubMed ID: 15917993
[TBL] [Abstract][Full Text] [Related]
4. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells.
Degli-Esposti MA; Davis-Smith T; Din WS; Smolak PJ; Goodwin RG; Smith CA
J Immunol; 1997 Feb; 158(4):1756-62. PubMed ID: 9029113
[TBL] [Abstract][Full Text] [Related]
5. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.
Zhai Y; Guo R; Hsu TL; Yu GL; Ni J; Kwon BS; Jiang GW; Lu J; Tan J; Ugustus M; Carter K; Rojas L; Zhu F; Lincoln C; Endress G; Xing L; Wang S; Oh KO; Gentz R; Ruben S; Lippman ME; Hsieh SL; Yang D
J Clin Invest; 1998 Sep; 102(6):1142-51. PubMed ID: 9739048
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor.
Morel Y; Schiano de Colella JM; Harrop J; Deen KC; Holmes SD; Wattam TA; Khandekar SS; Truneh A; Sweet RW; Gastaut JA; Olive D; Costello RT
J Immunol; 2000 Oct; 165(8):4397-404. PubMed ID: 11035077
[TBL] [Abstract][Full Text] [Related]
7. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth.
Harrop JA; McDonnell PC; Brigham-Burke M; Lyn SD; Minton J; Tan KB; Dede K; Spampanato J; Silverman C; Hensley P; DiPrinzio R; Emery JG; Deen K; Eichman C; Chabot-Fletcher M; Truneh A; Young PR
J Biol Chem; 1998 Oct; 273(42):27548-56. PubMed ID: 9765287
[TBL] [Abstract][Full Text] [Related]
8. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.
Mauri DN; Ebner R; Montgomery RI; Kochel KD; Cheung TC; Yu GL; Ruben S; Murphy M; Eisenberg RJ; Cohen GH; Spear PG; Ware CF
Immunity; 1998 Jan; 8(1):21-30. PubMed ID: 9462508
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of graft arterial disease by manipulation of the LIGHT pathway.
Kosuge H; Suzuki J; Kakuta T; Haraguchi G; Koga N; Futamatsu H; Gotoh R; Inobe M; Isobe M; Uede T
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1409-15. PubMed ID: 15178556
[TBL] [Abstract][Full Text] [Related]
10. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function.
Wang J; Foster A; Chin R; Yu P; Sun Y; Wang Y; Pfeffer K; Fu YX
Eur J Immunol; 2002 Jul; 32(7):1969-79. PubMed ID: 12115617
[TBL] [Abstract][Full Text] [Related]
11. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells.
Stopfer P; Männel DN; Hehlgans T
J Immunol; 2004 Jun; 172(12):7459-65. PubMed ID: 15187124
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.
Gill RM; Ni J; Hunt JS
Am J Pathol; 2002 Dec; 161(6):2011-7. PubMed ID: 12466117
[TBL] [Abstract][Full Text] [Related]
13. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.
Yu KY; Kwon B; Ni J; Zhai Y; Ebner R; Kwon BS
J Biol Chem; 1999 May; 274(20):13733-6. PubMed ID: 10318773
[TBL] [Abstract][Full Text] [Related]
14. The lymphotoxin pathway: beyond lymph node development.
McCarthy DD; Summers-Deluca L; Vu F; Chiu S; Gao Y; Gommerman JL
Immunol Res; 2006; 35(1-2):41-54. PubMed ID: 17003508
[TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis.
Scheu S; Alferink J; Pötzel T; Barchet W; Kalinke U; Pfeffer K
J Exp Med; 2002 Jun; 195(12):1613-24. PubMed ID: 12070288
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lymphotoxin-beta receptor-mediated cell death by survivin-DeltaEx3.
You RI; Chen MC; Wang HW; Chou YC; Lin CH; Hsieh SL
Cancer Res; 2006 Mar; 66(6):3051-61. PubMed ID: 16540654
[TBL] [Abstract][Full Text] [Related]
17. LIGHT, a member of the TNF superfamily, induces morphological changes and delays proliferation in the human rhabdomyosarcoma cell line RD.
Hikichi Y; Matsui H; Tsuji I; Nishi K; Yamada T; Shintani Y; Onda H
Biochem Biophys Res Commun; 2001 Dec; 289(3):670-7. PubMed ID: 11726199
[TBL] [Abstract][Full Text] [Related]
18. Lymphotoxin-β receptor activation by lymphotoxin-α(1)β(2) and LIGHT promotes tumor growth in an NFκB-dependent manner.
Daller B; Müsch W; Röhrl J; Tumanov AV; Nedospasov SA; Männel DN; Schneider-Brachert W; Hehlgans T
Int J Cancer; 2011 Mar; 128(6):1363-70. PubMed ID: 20473944
[TBL] [Abstract][Full Text] [Related]
19. The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA.
Sarrias MR; Whitbeck JC; Rooney I; Ware CF; Eisenberg RJ; Cohen GH; Lambris JD
Mol Immunol; 2000 Aug; 37(11):665-73. PubMed ID: 11164894
[TBL] [Abstract][Full Text] [Related]
20. IL-2-induced tumor necrosis factor (TNF)-beta expression: further analysis in the IL-2 knockout model, and comparison with TNF-alpha, lymphotoxin-beta, TNFR1 and TNFR2 modulation.
Reddy J; Chastagner P; Fiette L; Liu X; Thèze J
Int Immunol; 2001 Feb; 13(2):135-47. PubMed ID: 11157847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
